Investing.com - Windtree Therapeutics reported on Monday third quarter earnings that beat analysts' forecasts and revenue that was in line with expectations.
Windtree Therapeutics announced earnings per share of $-0.130 on revenue of $50K. Analysts polled by Investing.com anticipated EPS of $-0.260 on revenue of $50K.
Windtree Therapeutics shares are down 89% from the beginning of the year, still down 90.17% from its 52 week high of $1.78 set on November 29, 2021.
Windtree Therapeutics shares lost 2.83% in intra-day trade following the report.
Windtree Therapeutics follows other major Healthcare sector earnings this month
Windtree Therapeutics's report follows an earnings beat by J&J on October 18, who reported EPS of $2.55 on revenue of $23.79B, compared to forecasts EPS of $2.48 on revenue of $23.36B.
Eli Lilly had beat expectations on November 1 with third quarter EPS of $1.98 on revenue of $6.94B, compared to forecast for EPS of $1.91 on revenue of $6.91B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar